T-cell receptor specific for ODI-2001 neoepitope–MHC complex (ODI-2001 Neoepitope-MHC)

The T-cell receptors (TCRs) specific for ODI-2001 neoepitope–MHC complexes are the primary immune effectors induced by the ODI-2001 personalized therapeutic vaccine program. ODI-2001 is a precision medicine initiative that utilizes the OncoSNIPE platform to identify patient-specific neoantigens—mutated proteins unique to an individual's tumor—which are then presented by Major Histocompatibility Complex (MHC) molecules on the cell surface. These neoepitope-MHC complexes serve as highly specific targets for the immune system, as they are absent from healthy tissues, thereby minimizing off-target toxicity. The therapeutic strategy involves vaccinating patients with these neoepitopes to expand and activate a repertoire of endogenous T-cells bearing TCRs that can recognize and eliminate tumor cells. This approach is currently being explored for the treatment of various solid tumors, aiming to provide a durable, personalized anti-tumor immune response.

Other names

Neoepitope-MHC complexNeoantigen-HLA complexTumor-specific neoepitope-MHCODI-2001 target complex

The therapeutic vaccine (ODI-2001) delivers patient-specific neoepitopes to antigen-presenting cells, which then present these peptides on MHC molecules to prime and expand T-cells. These activated T-cells express T-cell receptors (TCRs) that specifically bind to the Neoepitope-MHC complexes on the surface of tumor cells, triggering the release of cytotoxic granules (perforin and granzymes) and inducing apoptosis in the target cancer cells.